| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6242794 | Academic Radiology | 2013 | 7 Pages |
Abstract
Our initial data indicate that aChoi-criteria can reflect response to vemurafenib earlier compared to RECIST. This is of clinical significance as BRAF-inhibitors are cost-intensive targeted therapies and can cause severe side effects, so criteria for early therapy response have to be evaluated.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Monika MD, Jessica C. MD, Heinz-Peter MD, Maria-Katharina MD,